How should psychosis associated with naltrexone (opioid receptor antagonist) be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Naltrexone-Associated Psychosis

Naltrexone-associated psychosis should be managed by immediate discontinuation of naltrexone, followed by antipsychotic medication if symptoms persist, and consideration of alternative pharmacotherapy for the original indication.

Initial Management

  • Immediate discontinuation of naltrexone is the first and most crucial step when psychosis is suspected to be medication-induced 1
  • Monitor vital signs and assess for other potential causes of psychotic symptoms
  • Visual hallucinations appear to be the most commonly reported psychotic symptom associated with naltrexone 1
  • Document the timeline between naltrexone initiation and onset of psychotic symptoms to establish causality

Acute Symptom Management

If psychotic symptoms persist after discontinuation:

  • Short-term antipsychotic medication may be necessary
  • Benzodiazepines can be used as adjuncts for severe agitation
  • Avoid using antipsychotics as stand-alone medications for withdrawal symptoms, as they should only be used as adjuncts to benzodiazepines in severe withdrawal delirium that has not responded to adequate doses of benzodiazepines 2

Alternative Treatment Options

After resolution of psychotic symptoms, consider alternative pharmacotherapy for the original indication:

For Alcohol Use Disorder:

  • Acamprosate is a safer alternative for patients who experienced psychosis with naltrexone 2
  • Disulfiram may be considered as it has shown approximate equivalence with naltrexone in effectiveness for alcohol use disorder in patients with comorbid psychosis 3

For Opioid Use Disorder:

  • Buprenorphine (8-16 mg daily) is recommended as an effective approach for managing patients who cannot tolerate naltrexone 4
  • For patients with chronic pain, higher doses of buprenorphine divided throughout the day may be needed 4

For Obesity Management:

  • Consider alternative weight management medications such as liraglutide 3.0 mg, which works through a different mechanism (GLP-1 receptor agonist) 2
  • Intensive behavioral modification should be emphasized

Risk Assessment and Monitoring

  • Patients with a history of psychotic disorders are at higher risk for naltrexone-associated psychosis 3, 5
  • In patients with schizophrenia, schizoaffective disorder, or bipolar disorder, careful monitoring is essential if naltrexone is used 6
  • These patients had worse alcohol outcomes than those without psychotic spectrum disorders but still benefited from medication treatment compared to placebo 6

Follow-up Care

  • After discontinuation of naltrexone and resolution of psychotic symptoms:
    • Reassess the patient's underlying condition requiring naltrexone
    • Document naltrexone-induced psychosis in the medical record as a medication allergy/adverse reaction
    • Consider psychiatric consultation if symptoms persist beyond 1-2 weeks after discontinuation
    • Monitor for withdrawal symptoms if naltrexone was being used for substance use disorder

Prevention Strategies

For patients requiring opioid antagonist therapy with risk factors for psychosis:

  • Consider starting with lower doses of naltrexone and titrating slowly
  • Implement more frequent monitoring during initiation phase
  • Educate patients and caregivers about early warning signs of psychosis
  • Consider alternative medications when possible for high-risk patients

Special Considerations

  • In patients with comorbid psychiatric illness and substance use disorders, retention rates and medication compliance can exceed 80% with appropriate support 6
  • The combination of pharmacotherapy with psychosocial interventions is essential for optimal outcomes 2
  • Patients with a history of self-injurious behavior who benefited from naltrexone may require alternative treatments such as dialectical behavior therapy if naltrexone must be discontinued 7

References

Research

Naltrexone-associated Visual Hallucinations: A Case Report.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Kratom Withdrawal

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.